Data / Drug companies / Eptifibatide
Eptifibatide: 9 companies and 21 products in the FDA NDC directory
Eptifibatide is listed in the FDA National Drug Code Directory by 9 companies, with 21 products in commercial distribution. 21 of the products (100.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection, solution; injection, and the newest product started marketing on May 9, 2024.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 9
- Products
- 21
- Generic (ANDA) products
- 21 (100.0%)
- Application numbers
- 7
- Routes
- Intravenous
- openFDA record search
- api.fda.gov
Companies that list eptifibatide
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Slate Run Pharmaceuticals, LLC | 4 | injection | Generic drugs (ANDA) | July 22, 2019 |
| Eugia US LLC | 3 | injection | Generic drugs (ANDA) | December 8, 2015 |
| Mylan Institutional LLC | 3 | injection, solution | Generic drugs (ANDA) | April 1, 2021 |
| Mylan Institutional LLC | 3 | injection, solution | Generic drugs (ANDA) | December 13, 2018 |
| Avenacy, LLC | 2 | injection, solution | Generic drugs (ANDA) | January 31, 2024 |
| Hainan Shuangcheng Pharmaceuticals Co., Ltd. | 2 | injection, solution | Generic drugs (ANDA) | April 21, 2022 |
| Meitheal Pharmaceuticals Inc. | 2 | injection, solution | Generic drugs (ANDA) | May 9, 2024 |
| Baxter Healthcare Corporation | 1 | injection | Generic drugs (ANDA) | February 1, 2019 |
| Sagent Pharmaceuticals | 1 | injection, solution | Generic drugs (ANDA) | July 15, 2018 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 13 | 61.9% |
| Injection | 8 | 38.1% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 21 | 100% |
Pharmacologic classes
| Class | Products |
|---|---|
| Platelet Aggregation Inhibitor | 21 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.